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Telomere length is maintained by two known mechanisms,
the activation of telomerase or alternative lengthening of
telomeres (ALT). The molecular mechanisms regulating
the ALT phenotype are poorly understood and it is
unknown how the decision of which pathway to activate is
made at the cellular level. We have shown earlier that
active repression of telomerase gene expression by
chromatin remodelling of the promoters is one mechanism
of regulation; however, other genes and signalling net-
works are likely to be required to regulate telomerase and
maintain the ALT phenotype. Using gene expression
proﬁling, we have uncovered a signature of 1305 genes to
distinguish telomerase-positive and ALT cell lines. By
combining this with the gene expression proﬁles of lipo-
sarcoma tissue samples, we reﬁned this signature to 297
genes. A network analysis of known interactions between
genes within this signature revealed a regulatory signalling
network consistent with a model of human telomerase
reverse transcriptase (hTERT) repression in ALT cell lines
and liposarcomas. This network expands on our existing
knowledge of hTERT regulation and provides a platform
to understand differential regulation of hTERT in different
tumour types and normal tissues. We also show evidence
to suggest a novel mesenchymal stem cell origin for ALT
immortalization in cell lines and mesenchymal tissues.
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Introduction
A central hallmark of cancer cells is their capacity
for unlimited proliferation, made possible partly by
telomere length maintenance. Most human tumours
maintain telomeres by activating telomerase; however,
in a smaller subset of tumours, maintenance occurs in
the absence of telomerase through a recombination-
based mechanism termed alternative lengthening of
telomeres (ALT). The ALT is characterized phenotypi-
cally by long, heterogeneous telomeres and the presence
of ALT-associated promyelocytic leukaemia bodies,
which contain telomeric DNA, telomere-binding pro-
teins such as telomere repeat binding factors 1 and 2 and
proteins implicated in DNA recombination and replica-
tion, including Mre11-Rad50-Nbs1 complex proteins
MRE11, RAD51 and NBS (Yeager et al., 1999; Henson
et al., 2002). Association of these proteins with the ALT
phenotype make them attractive as potential markers or
regulators of ALT (Jiang et al., 2007); indeed, the MRN
complex is required for ALT-associated promyelocytic
leukaemia body formation and telomere maintenance in
ALT cells (Zhong et al., 2007).
Although the overall prevalence of ALT in tumours is
relatively low, it is observed at high frequency in
tumours of mesenchymal origin. However, the preva-
lence of ALT varies even within this group. About 77%
of malignant ﬁbrous histiocytomas (Henson et al., 2005)
and 47–66% of osteosarcomas (Ulaner et al., 2003;
Henson et al., 2005) were shown to be ALT positive,
whereas 25% of glioblastoma multiforme (Hakin-Smith
et al., 2003) and liposarcomas (Johnson et al., 2005;
Costa et al., 2006) and no Ewing’s sarcomas (Ulaner
et al., 2004) showed evidence of ALT. Since the prog-
nostic signiﬁcance of ALT varies, signifying a good
prognosis for patients with glioblastoma multiforme
but a poor prognosis for those with liposarcoma (Costa
et al., 2006; Cairney et al., 2008), and understanding
the molecular details regulating ALT immortalization
and the cell of origin may impact future diagnosis or
treatment of these malignancies.
A possible explanation for the prevalence of ALT in
mesenchymal malignancies is that the telomerase genes
are more tightly repressed in mesenchymal tissues over
those of epithelial origin (Henson et al., 2002). We have
earlier reported that both human telomerase RNA and
human telomerase reverse transcriptase (hTERT) are
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actively repressed at the chromatin level in ALT cell
lines (Atkinson et al., 2005), suggesting forced repres-
sion of telomerase as one potential molecular mechan-
ism promoting immortalization by ALT. However,
other genes and signalling networks also regulate
telomerase and may contribute to the decision of
selecting ALT versus telomerase. In this study we
investigate the gene expression proﬁles of telomerase-
positive and ALT cell lines and liposarcoma tissue
samples to better understand the molecular mechanisms
regulating the decision to activate telomerase or ALT.
In addition, we show a link between mesenchymal
tumours and human mesenchymal stem cells
(hMSCs) as the target cell for transformation in ALT
immortalization.
Results
Gene expression analysis distinguishes telomerase and
ALT cell lines
We initially investigated the presence of a telomere
maintenance mechanism (TMM)-speciﬁc gene expres-
sion signature by generating expression proﬁles for four
ALT and four telomerase-positive cell lines using
Agilent whole human genome 1-colour microarrays
(Agilent Technologies, Santa Clara, CA, USA). A
detailed description of the quality control measures
and the normalization options applied can be found in
the section Materials and methods; however, boxplots
show that the normalized data are equally spread and
comparable between the two groups (Figure 1a), with
virtually equal medians of 0.78 and 0.79 for ALT and
telomerase-positive cell line groups, respectively.
To explore the possibility that expression of indivi-
dual genes within these large proﬁles is responsible for
deﬁning either telomerase-positive or ALT cells, we
performed Welch’s analysis of variance test to look for
signiﬁcant differences in gene expression between the
two groups (Figure 1b, left panel). A list of 1307 probes
corresponding to 1305 differentially expressed genes
with a P-value ofp0.05 was generated. By focussing on
the expression values for individual genes within the
larger 1305 gene signature, it was clear that whereas
expression was high in the ALT cell lines it was low in
the telomerase-positive cell lines and vice versa
(Figure 2a). Furthermore, hierarchical clustering of the
cell lines on the basis of this signature helped to
accurately bifurcate ALT and telomerase-positive cell
lines into two separate groups (Figure 2b), suggesting
that the genes responsible for deﬁning telomerase or
ALT or those involved in regulating the decision of
which TMM to activate may lie within this signature.
Clustering by using the 1305 gene signature is suggestive
of a mesenchymal stem cell origin for ALT
The fact that ALT is predominantly found in tumours of
mesenchymal origin prompted us to investigate whether
ALT is a function of the cell of transformation and
whether mesenchymal stem cells could be the potential
cell of origin for ALT tumours. We performed a
hierarchical clustering analysis by using the 1305 gene
signature to investigate any relationship between telo-
merase-positive, ALT and normal ﬁbroblast cell lines,
and hMSCs (Figure 2c). The signature helped to
accurately separate telomerase-positive and ALT cell
lines, normal ﬁbroblasts, and hMSCs. However,
whereas the telomerase-positive cell lines clustered
together on a separate branch, the ALT cell lines,
normal ﬁbroblasts and hMSCs all clustered together.
Normal ﬁbroblasts are more directly related to hMSCs
than ALT; however, ﬁbroblasts and hMSCs are equally
related to the ALT cell lines, suggesting a mesenchymal
stem cell origin for ALT. This might be as predicted;
however, to our knowledge, this is the ﬁrst time any
association between mesenchymal stem cells and ALT
has been shown.
Analysis of the signature revealed several genes
associated with stem cell maintenance, and self-renewal
processes were differentially expressed between telomer-
ase-positive and ALT cell lines. Four of these genes with
strong differences in expression were chosen for valida-
tion by quantitative PCR (Q-PCR) (Figure 3a). Three of
these genes were signiﬁcantly upregulated in ALT cell
lines and barely expressed in telomerase-positive cell
lines. DSC54 is a novel mesenchymal stem cell protein
for which little information exists; WNT5b is a well-
known regulator of stem cell function implicated in
oncogenesis and development; MYEOV is overex-
pressed in myeloma and has a role in promoting
invasion and proliferation; and the ﬁnal gene, NSUN5,
is a proliferation-associated nucleolar antigen, the
deletion of which may contribute to the premature
ageing effects of the developmental disorder William’s
syndrome. NSUN5 is signiﬁcantly upregulated in
telomerase-positive compared with ALT cell lines.
To further explore the link between ALT and
mesenchymal stem cells, we examined the expression
of these genes within a variety of normal tissues of
differing embryonic origin and hMSCs. The publicly
available gene expression proﬁles from normal ﬁbro-
blasts, smooth muscle, stromal, ectoepithelial, epithelial
and endothelial tissues were downloaded from the
National Centre for Biotechnology Information Gene
Expression Omnibus database and expression of
DSC54, WNT5b and MYEOV in these tissues was
compared with that of hMSC, telomerase-positive and
ALT cell lines (Figure 3b). No comparable data were
available for NSUN5, and therefore this gene could not
be included in the analysis.
Consistent with the Q-PCR validation, the expression
of all three genes is higher in ALT than in telomerase-
positive cell lines. When comparing all the expression
patterns, DSC54 is only high in ALT cell lines and
hMSCs, consistent with a mesenchymal stem cell origin
for ALT. In contrast, WNT5b shows varying expression
across the different tissue types and cell lines, with
highest expression in hMSC, ALT and mesenchymally
derived tissues and lowest expression in telomerase-
positive and epithelial tissues. MYEOV distinguishes
ALT from telomerase-positive cell lines; however, a
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similar low level of expression is seen across the various
other tissue types.
Reﬁnement of the 1305 gene signature using liposarcoma
gene expression improves separation of ALT and
telomerase-positive liposarcomas and suggests a
mesenchymal stem cell origin for ALT in this
mesenchymal malignancy
Liposarcomas are tumours of mesenchymal origin. In
order to reﬁne the cell line-derived signature with data
from primary tumours, we analysed the power of the
1305 gene expression signature to distinguish between
telomerase positive and ALT in liposarcomas. Gene
expression proﬁles were generated for a group of 17
previously characterized liposarcoma samples, of which
9 were ALT and 8 were telomerase positive. Unsuper-
vised clustering showed some split in the samples
depending on their TMM, which was not improved
when the 1305 gene signature was applied. Furthermore,
hMSCs did not cluster with any liposarcoma samples,
but clustered together on a separate branch (Figure 4,
compare a and b).
Although the 1305 signature does not improve
clustering, the liposarcoma samples, for the most part,
cluster together according to their TMM. The obvious
separation between ALT and telomerase-positive
tumours in the clustering diagram led us to believe that
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Figure 1 Gene expression analysis of alternative lengthening of telomeres (ALT) and telomerase-positive cell lines. (a) The boxplots
show distribution of normalized data in ALT and telomerase-positive cell line groups. Grey boxes deﬁne 25 and 75% quartiles,
whereas error bars represent the 1st and 99th percentiles of the distribution. Dots represent outliers, black line represents the median,
and the cross represents the mean of the distribution. (b) Overview of signature generation from cell line and liposarcoma tissue
samples. A reﬁned 297 gene signature was generated from a combination of the 1305 gene cell line signature and the 6719 gene
liposarcoma signature. This signature shows a potential mesenchymal stem cell origin for ALT and is involved in telomerase gene
regulation. Gene expression data were submitted to the National Center for Biotechnology Information Gene Expression Omnibus
(http://www.ncbi.nlm.nih.gov/geo/) under accession number GSE14533.
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differences in gene expression exist between the two
groups, although no signiﬁcant differences were found.
To explore this further, we used Fisher’s exact test to
test for any association between gene expression level
and TMM. From this analysis, 8227 probes correspond-
ing to 6719 genes were found to be signiﬁcantly
associated with TMM in ALT and telomerase-positive
liposarcoma samples (Figure 1b, right-hand panel).
To further reﬁne this large signature, we looked for
any overlap with the 1305 gene signature determined
from the cell lines previously. Of these 1305 genes, 422
genes are also present in the liposarcoma signature and
therefore have a signiﬁcant association with TMM in
liposarcoma and cell lines. Further reﬁnement of the
signature was carried out by looking at the direction
of gene expression in telomerase-positive and ALT
tumours in comparison with the cell line data. In total,
297 of the 422 genes had gene expression that was
comparable with the cell line data, 152 genes up in
ALT and down in telomerase-positive, and 145 genes
down in ALT and up in telomerase-positive (Figure 1b,
centre panel).
The hierarchical clustering of ALT and telomerase-
positive liposarcoma samples using this reﬁned 297 gene
signature showed a clear separation between the two
groups, with all except two ALT samples clustering
on one branch and all telomerase-positive samples
clustering together on a separate branch (Figure 4c).
Furthermore, consistent with the hypothesized mesench-
ymal stem cell origin for ALT seen within the cell
line data, hMSCs clustered with the ALT liposarcomas
using this reﬁned signature rather than as a separate
group when the 1305 signature was applied (Figure 4,
compare b and c).
To further verify the reﬁned signature, we applied it
back to the cell line data for hierarchical clustering. As
predicted, it accurately separated telomerase-positive
from ALT cell lines (data not shown), further validating
that this reﬁned signature holds true and no power is
lost by reducing gene number.
The reﬁned 297 gene signature is involved in telomerase
gene regulation and highlights lower c-MYC activity
in ALT
Given the ability of the reﬁned 297 gene signature to
separate liposarcomas by TMM, we hypothesized that
the genes within the signature may comprise functional
regulatory networks involved in aspects of TMM. To
explore this, we performed network modelling using
Metacore from Genego (St Joseph, MI, USA), allowing
us to build a candidate network indicating possible
interactions between genes from the 297 signature mined
from published data. A regulatory network involving
hTERT and telomeric DNA was revealed by this
analysis (Figure 4d). Expression data from the 297
gene signature were converted to fold change in ALT
over telomerase positive, uploaded into Metacore
analytical suite and overlaid on the direct interactions
network. As can be seen from Figure 4d, by combining
interactions between known signalling pathways and
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Figure 2 Gene expression proﬁling distinguishes telomerase-
positive and alternative lengthening of telomeres (ALT) cell lines
and is suggestive of a mesenchymal stem cell origin for ALT.
(a) Scatter plot representing normalized microarray expression
values for the 1305 gene signature in ALT (blue) and telomerase-
positive (red) cell lines relative to overall median expression value.
Each dot represents the mean gene expression values for a gene,
and error bars represent the standard error. (b) Hierarchical
clustering of the cell line data performed using the Spearman’s
correlation, average linkage and merging branches with a similarity
correlation of 0.001 or less with the 1305 signature accurately
separates telomerase positive (red) from ALT (blue) cell lines.
(c) Hierarchical clustering of telomerase-positive (red) and ALT
(blue) cell lines, normal ﬁbroblasts (purple) and human mesen-
chymal stem cells (hMSCs; green) performed using the Spearman’s
correlation, average linkage and merging branches with a similarity
correlation of 0.001 or less with the 1305 gene signature.
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experimentally deﬁned levels of expression for regula-
tory genes, this approach allows for predictions relating
to hTERT regulation and repression in ALT cells. The
hTERT expression is reduced in ALT cells and tumours
in relation to telomerase-positive samples. Consistent
with this, expression of E2F1, a known repressor of
hTERT, is upregulated in ALT samples, whereas the
expression of chromatin-modifying enzymes with roles
in gene activation, such as GCN5, are downregulated
in ALT, which is in agreement with the decreased
association of acetylated histones and low hTERT
expression in ALT cell lines as we have previously
shown. Western blotting of HDAC5, PKCa and
GCN5 (Figure 5a) shows that the expression differ-
ences highlighted in this network are also seen at the
protein level.
The analysis also indicates that c-Myc regulation may
contribute to the signature. Although c-Myc was not
itself differentially expressed, 21 signature genes includ-
ing hTERT are predicted transcriptional targets of
c-Myc. Interestingly, most signature genes expected to be
activated by c-Myc are repressed whereas those expected
to be inhibited are mainly upregulated in ALT, relative
to telomerase-positive samples, suggesting that c-Myc
activity may be suppressed in ALT. Functional exam-
ination of c-Myc activity levels using DNA-binding
activity enzyme-linked immunosorbent assays (ELISAs)
conﬁrms that this is indeed the case, as a signiﬁcantly
lower level of c-Myc activity is seen in the ALT cell lines
(P¼ 0.015; see Figure 5b). Apart from hTERT, another
downregulated c-Myc target that may have a role in
telomere maintenance is heterogeneous nuclear ribo-
nucleoprotein A3. It was recently shown that this gene
binds the single-stranded telomere repeat in vitro,
protects against nuclease activity and inhibits extension
by telomerase (Huang et al., 2008).
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Figure 3 Validation of the 1305 gene expression signature highlights a stem cell link. (a) Expression levels of DSC54, WNT5B,
MYEOV and NSUN5 were validated by quantitative PCR in telomerase-positive cell lines 5637, A2780, C33a and HT1080 (black
bars) and alternative lengthening of telomeres (ALT) cell lines WI38-SV40, KMST6, SKLU, SUSM1 (grey bars) cell lines. Each bar
represents the mean and standard error of triplicate reactions from a representative experiment normalized to glyceraldehyde
3-phosphate dehydrogenase. (b) Expression values for DSC54, WNT5B andMYEOV in various normal tissues extracted from publicly
available microarray expression data, compared with those for ALT and telomerase-positive cell lines and human mesenchymal stem
cells (hMSCs). Dots represent the median and the error bars represent the maximum and minimum normalized expression values.
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hMSCTel +ALT Tel + hMSCTel +ALT hMSC ALT
Figure 4 Hierarchical clustering of alternative lengthening of telomeres (ALT) and telomerase-positive liposarcoma samples and
human mesenchymal stem cells (hMSCs) distinguishes telomerase-positive from ALT and highlights an hMSC origin for ALT.
Liposarcoma samples were previously determined as ALT (blue) or telomerase-positive (red) by classical methods. Hierarchical
clustering of these samples and hMSC (green) was performed using the Spearman’s correlation, average linkage and merging branches
with a similarity correlation of 0.001 or less, using (a) all genes (b) 1305 gene signature or (c) the reﬁned 297 gene signature.
(d) Network analysis of the 297 gene signature shows hTERT regulation. Signalling network of known direct interactions between
genes from the 297 gene signature drawn using the analyse network-building algorithm within Metacore. Green arrows represent
positive, red negative and grey unspeciﬁed interactions. Red and blue circles next to the network objects represent expression data.
Red: up in ALT and down in telomerase-positive liposarcoma samples and cell lines; Blue: down in ALT and up in telomerase-positive
liposarcoma samples and cell lines. The network highlights that a number of molecules activated by c-Myc have reduced expression
in ALT cells and those inhibited by c-Myc have increased expression in ALT cells. This is suggestive of lower c-Myc activity in cells
using ALT.
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More importantly, however, network analysis ex-
pands our understanding of TERT regulation beyond
previously recognized mechanisms to new pathways
upstream of those already known to be involved.
Overall, this network highlights a potential mechanism
of regulating the ALT phenotype through repression of
hTERT and provides a platform for further expansions
of regulatory mechanisms present in tissue or tumour-
speciﬁc situations to enable us to understand the
differential regulation of biological processes and how
they vary in different tumour types and normal tissues.
Discussion
The molecular mechanisms regulating the decision to
activate telomerase or ALT during tumourigenesis are
currently poorly understood. We have shown earlier
that lack of expression of the telomerase genes human
telomerase RNA and hTERT is associated with
chromatin remodelling at the promoters, suggesting
that forced repression of these genes may cause the cells
to utilize the ALT mechanism for immortalization
(Atkinson et al., 2005). In this study, we have used
gene expression proﬁling of telomerase and ALT cell
lines and liposarcomas to investigate other signalling
pathways and networks that may be operating to
control the ALT phenotype and the decision to activate
telomerase or ALT for immortalization. To our knowl-
edge, this is the ﬁrst study of global gene regulation
of TMM.
We uncovered a gene expression signature with the
power to distinguish telomerase positive and ALT
through hierarchical clustering methods in tumour cell
lines. Further reﬁnement of this signature using gene
expression proﬁles from liposarcoma tissue samples
revealed a 297 gene signature that has signiﬁcant
association with TMM. Although the role of these
signatures in the regulation of the ALT phenotype
remains to be fully investigated, we have uncovered
some of the underlying biology by combining clinical
samples with cell line proﬁles. A network analysis of
interactions within the reﬁned signature highlighted a
signalling network involved in repression of hTERT in
ALT liposarcoma samples and cell lines. Western blot
validation of three of the molecules in the network
conﬁrmed that this pattern can also be observed at the
protein level. Consistent with our earlier work (Atkin-
son et al., 2005; Cairney et al., 2008), this again points to
forced repression of hTERT in ALT and may in part
explain the decision to activate telomerase or ALT at the
molecular level. Although hTERT expression alone is
insufﬁcient to discriminate ALT and telomerase positive
in clinical samples, hTERT repression is clearly im-
portant for regulation of the ALT phenotype. This
network of interactions also highlighted the potential for
lower c-Myc activity in cells using the ALT mechanism.
Upon direct investigation using c-Myc activity ELISAs,
a lower level of c-Myc activity in ALT was conﬁrmed.
This is consistent with the fact that c-Myc is a known
hTERT transcriptional activator (Hao et al., 2008) and
may show a further mechanism by which the decision to
activate either ALT or telomerase is inﬂuenced.
This candidate network further highlights the im-
portance of a global analysis of gene expression. Where
signiﬁcant expression of one gene may be of importance
in certain circumstances, it is more likely, as evidenced
by this example, that small changes in a combination of
genes in a signalling pathway are responsible for
deﬁning a phenotype. By investigating signalling net-
works on a global scale, we are better advantaged to
discover the biology underlying the ALT phenotype and
its regulation in mesenchymal malignancies.
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Figure 5 The telomerase reverse transcriptase (TERT) regulatory network is shown at the protein level and predicted c-MYC activity
is conﬁrmed as signiﬁcantly lower in alternative lengthening of telomeres (ALT). (a) Western blotting shows protein level differences in
three molecules of the 297 gene network. Fifteen micrograms of cell extracts were run on NuPAGE 4–12% Bis–Tris gels, transferred to
Millipore nitrocellulose membrane and probed with appropriate antibodies. Blots were then stripped and reprobed with extracellular
signal-regulated kinase 1 loading control. The panels shown are representative panels of two separate blots. (b) Analysis of c-Myc
activity using enzyme-linked immunosorbent assay (ELISA) shows signiﬁcantly lower activity in ALT cells. The interval plot shows the
average of six ALT cell lines (WI38-SV40, KMST6, SKLU, SUSM1, SAOS and U2OS) and four telomerase cell lines (A2780, C33a,
HT1080 and 5637) on three separate occasions with four replicates of each cell line. Crosshairs show the mean expression for each
group and error bars show 95% conﬁdence intervals of the mean. The t-test results were t-value¼ 2.51; P-value¼ 0.015; d.f.¼ 51.
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In addition to the hTERT regulatory network, a
number of stem cell-related genes were also highlighted
within the large gene signature. The possibility that the
decision to activate either telomerase or ALT is made at
the cellular level is an interesting hypothesis to consider.
Cancer biology in many ways parallels that of stem cell
biology as pathways regulating the self-renewal pheno-
type and replicative lifespan of stem cells are commonly
deregulated in cancer. With the growing interest in stem
cells as the cell of origin for certain tumours, investigat-
ing the potential origin for ALT immortality may
improve our understanding of the regulation of telomere
maintenance. The preponderance of ALT in mesen-
chymal malignancies prompted us to investigate any
relationship between hMSCs and ALT or telomerase-
positive cell lines and liposarcoma tissues. hMSCs are an
adult stem cell population with limited replicative
lifespan and no detectable telomerase activity (Zimmer-
mann et al., 2003), which is at least partly due to active
repression of the telomerase genes at the chromatin
level, similar to the situation in ALT cell lines (Serakinci
et al., 2006; Cairney and Keith, 2008). However, hMSCs
do not show characteristic molecular markers of ALT
(Bernardo et al., 2007; Zhao et al., 2008). It is therefore
possible that hMSCs upon transformation could be-
come either ALT or telomerase-positive tumours. There
is, however, a need for accurate models of the molecular
details of the decision between these two mechanisms,
such as ours, before manipulation of the resulting TMM
can be achieved.
Hierarchical clustering showed that the expression
proﬁle of the signature genes in hMSCs was more closely
related to ALT than to telomerase-positive cell lines with
the larger signature, and also to ALT liposarcomas when
the reﬁned 297 gene signature was utilized, suggesting a
mesenchymal stem cell origin for ALT.
Mesenchymal stem cells are known to be potential
targets for transformation in vitro. Lack of any TMM in
these cells may be a tumour suppressor mechanism, as
transduction with hTERT has been shown to extend
their lifespan and induce neoplastic characteristics after
long-term culture in vitro and tumour formation in vivo
(Serakinci et al., 2004). In addition, several studies have
shown the ability of MSC to transform spontaneously
after long-term culture in vitro in murine systems (Miura
et al., 2006; Zhou et al., 2006), although the situation in
human systems remains unclear, with conﬂicting reports
suggesting that the capacity for spontaneous transfor-
mation may be dependant on the tissue of origin (Rubio
et al., 2005; Wang et al., 2005; Miura et al., 2006;
Bernardo et al., 2007). More recently, several studies
have linked hMSCs with mesenchymal malignancies,
including Ewing’s sarcoma (Tirode et al., 2007; Riggi
et al., 2008) and malignant ﬁbrous histiocytoma
(Matushansky et al., 2007). Stem-like tumour-initiating
cells have also been isolated from various mesenchymal
tumours (Gibbs et al., 2005; Wu et al., 2007). Taken
together, these data suggest that the stem cell origin for
cancer extends to mesenchymal malignancies.
Although the preponderance of ALT in mesenchymal
tissues has been documented previously on numerous
occasions, to our knowledge this is the ﬁrst time the link
to a mesenchymal stem cell origin for ALT has been
made. Furthermore, this is not simply reﬂective of
the mesenchymal origin of ALT cell lines as both the
ALT and telomerase-positive liposarcoma samples are
mesenchymally derived and only the ALT liposarcomas
cluster with hMSCs. The signiﬁcance of this association
is unknown at present, but certainly warrants further
investigation.
In conclusion, we have uncovered a gene expression
signature capable of distinguishing telomerase-positive
from ALT in cell lines and liposarcoma tissue samples.
This signature contains a regulatory signalling network
involving hTERT repression in ALT and is indicative of
a novel hMSC origin for ALT. The results presented
allow us to postulate two potential models for the target
cell of origin for ALT and telomerase immortalization:
either (1) two separate cells of origin exist for
telomerase-positive and ALT-expressing malignancies
or (2) telomerase-positive and ALT tumours arise from
the same cell of origin. In the latter case, the cell of
origin would be the hMSCs, whereby telomerase-
positive tumours obtain molecular proﬁles over time
that diversify them from the hMSC origin, whereas ALT
tumours maintain the stem cell proﬁle, perhaps in part
through mechanisms such as repression of the telomer-
ase genes. The data presented here favour the latter
scenario; however, further investigation is required in
the other tumour types known to utilize the ALT
mechanism, such as glioma (Chen et al., 2006),
adrenocortical carcinoma, breast carcinoma, malignant
melanoma, lung carcinoma, ovarian carcinoma (Bryan
et al., 1997) and renal carcinoma (Mehle et al., 1996). A
better understanding of the regulation of TMM in the
cell of origin will increase our knowledge of the biology
underlying these tumour types and may highlight novel
areas for therapeutic intervention.
Materials and methods
Cell lines and RNA extraction
The ALT cell lines used were SKLU (lung adenocarcinoma),
SUSM1 (liver ﬁbroblasts), KMST6 (lung ﬁbroblasts), WI38-
SV40 (SV40 immortalized lung ﬁbroblasts), SAOS (osteosarco-
ma) and U2OS (osteosarcoma). Telomerase-positive cells used
were C33a (cervical carcinoma), HT1080 (ﬁbrosarcoma), A2780
(ovarian carcinoma) and 5637 (bladder carcinoma). Normal cell
strains used were WI38 (normal lung ﬁbroblasts) and IMR90
(normal lung ﬁbroblasts). Bone marrow hMSCs were isolated as
described earlier (Serakinci et al., 2006) and cultured using
Dulbecco’s modiﬁed Eagle’s medium with low glucose plus
Glutamax supplemented with 17% Hyclone fetal bovine serum
(Thermo Fisher Scientiﬁc, Waltham, MA, USA) at 5% CO2.
RNA was extracted using the Nucleospin II RNA extraction
kit (Macherey-Nagel, Duren, Germany) following the manu-
facturers’ instructions.
Liposarcoma cases and RNA extraction
A subset of 17 liposarcoma samples (9 ALT and 8 telomerase
positive) from a larger study population earlier described
(Cairney et al., 2008) were used for gene expression analysis.
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Frozen tissue was disrupted using a Hybaid Ribolyser
(Hybaid, Teddington, UK) at a setting of 5.5 for 5 10 s pulses
with 30-s pauses in between and RNA was extracted using the
RNeasy Lipid kit (Qiagen Inc., Hilden, Germany) as per the
manufacturers’ instructions.
Gene expression microarray hybridization, normalization and
quality control
In total, 4 ALT cell lines (WI38-SV40, KMST6, SKLU and
SUSM1) and 4 telomerase-positive cell lines (A2780, C33a,
HT1080 and 5637), 2 normal ﬁbroblasts (WI38, IMR90), 4
hMSCs and 17 liposarcoma samples were examined using gene
expression microarrays. Two separate RNA samples for each
were ampliﬁed and labelled using the Agilent Low RNA Input
Linear Ampliﬁcation Kit PLUS, 1-colour and hybridized to
Agilent whole human genome 4 44K gene expression arrays
as per the manufacturers’ instructions. Raw data were
extracted from scanned images using Agilent feature extraction
software (Agilent Technologies).
All array data was then imported into GeneSpring GX
(version 7.3.1, Agilent Technologies) and normalised to the
50th, for cell line arrays, or 70th percentile for hMSC and
liposarcoma arrays respectively to ensure equal medians
across all samples. Further quality control involved ﬁltering
based on ﬂag values where only those genes that had non-
absent ﬂag values for at least half of the samples were included
in downstream analysis. A box plot of the distribution of the
resulting genome (Figure 1a) was plotted using Minitab version
14 (Minitab, Coventry, UK) to assess comparability of groups.
Data ﬁles submitted to GEO for Public access under accession
number GSE14533.
Statistical analysis, signature generation and clustering
All statistical analysis and signature generation were carried
out within GeneSpring GX. The 1305 gene signature was
generated from cell line expression proﬁles using Welch’s
analysis of variance with a false discovery rate of 0.05 and
Benjamini and Hochberg multiple testing correction. A similar
analysis in liposarcoma samples generated no results and
therefore to generate the reﬁned 297 gene signature, Fisher’s
exact test using a P-value of p0.05 was performed using the
liposarcoma expression proﬁles to test for signiﬁcant associa-
tion of gene expression with TMM. From this analysis, 422
genes were also present within the 1305 signature. The genes
that had fold-change values in the same direction for both cell
line and liposarcoma data (that is, an increased or decreased
expression in ALT compared with telomerase positive) were
included in the reﬁned signature.
All hierarchical clustering was performed using the Spear-
man’s correlation, average linkage and merging branches with
a similarity correlation of p0.001.
Q-PCR validation of microarray data
Expression of some genes within the 1305 signature was
validated by Q-PCR using the DyNAmo Hot Star SYBR
Green Kit (Finnzymes, Espoo, Finland) and Opticon 2
DNA Engine from MJ Research (Waltham, MA, USA).
Primer sequences for Q-PCR validation were as follows:
MYEOVF: 50-TGGGAGGACACGCAAGTT, MYEOVR:
50-CCAGCAGCCAAAGCAAAG, WNT5BF: 50-AGGAGG
GAGGTTGTGGTT, WNT5BR: 50-GAACCGTGGAGGAT
GAAG, DSC54F: 50-ACCCTTCTACGAAATGGA, DSC54R:
50-ACTGTGGCTTATTCCCAT, NSUN5F: 50-TGAGACC
ACACTCAGCAG and NSUN5R: 50-GAGAGGACAGGCA
TCTTC.
Expression of each gene was normalized to glyceraldehyde
3-phosphate dehydrogenase as a loading control: GAPDHF:
50-ACCACAGTCCATGCCATCAC, GAPDHR: 50-TCCAC
CACCCTGTTGCTGTA.
Analysis of public data
Normalized gene expression data for a compendium of 61
samples from various normal cell types were downloaded from
the National Center for Biotechnology Information Gene
Expression Omnibus (series GSE3239). Comparison with cell
line and hMSC data was carried out in Microsoft Excel.
Network analysis in Metacore
Expression data from the 297 gene signature were converted to
fold change in ALT over telomerase positive and uploaded into
Metacore analytical suite. Network analysis was performed using
the analyse network algorithm within the software.
Western blotting validation of network analysis
Fifteen micrograms of protein equivalents were separated on
10% Bis–Tris gels using NuPAGE MES running buffer
(Invitrogen, Renfrewshire, UK), and then blotted onto
nitrocellulose membrane (Millipore, Watford, UK) and
blocked in phosphate buffered saline Tween-20 containing
5% nonfat dried milk. Membranes were probed with
the following antibodies: HDAC5 rabbit polyclonal (Active
Motif, Rixenstart, Belgium), PKCa rabbit polyclonal and
KAT2A/GCN5 rabbit polyclonal (both from Abcam,
Cambridge, UK) and secondary anti-rabbit IgG horseradish
peroxidase-linked antibody (New England Biolabs UK,
Hitchin, UK). After visualization, membranes were stripped
of bound primary and secondary antibodies by submerging
in 1% SDS and 0.2m glycine (pH 2.5) and shaken for 1 h at
room temperature, and rinsed and reblocked before probing
with loading control antibody extracellular signal-regulated
kinase 1 rabbit polyclonal (1:3000) (Santa Cruz Biotechnology,
Heidelberg, Germany).
c-MYC DNA-binding ELISA
Nuclear extracts of approximately 8 108 cells of each of the six
ALT cell lines (WI38-SV40, KMST6, SKLU, SUSM1, SAOS
and U2OS) and four telomerase-positive cell lines (A2780, C33a,
HT1080 and 5637) were extracted in triplicate using an Active
motif nuclear extraction kit (Active Motif, Rixenstart, Belgium)
as per the manufacturer’s instructions. c-MYC DNA-binding
ELISAs (Active Motif) were performed on three separate
occasions with four technical replicates of each cell line as per
the manufacturer’s instructions. A standard curve of 5, 2.5, 1.25
and 0.625ng/well recombinant c-MYC protein (Active Motif)
was run on each assay to allow relative quantiﬁcation. Results of
all ALT and telomerase-positive cells were grouped and a t-test
was carried out using Minitab (version 14).
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